Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary

July 30, 2020

NASDAQ US Health Care Biotechnology earnings 31 min

Earnings Call Speaker Segments

Zack Kubow

executive
#1

Thanks a lot, operator, and good afternoon to all of you. We appreciate you being here for Corvus Pharmaceuticals' conference call covering our Second Quarter 2020 Business Update and Financial Results. Joining us today to go over the quarter 2020 results and business highlights are Richard Miller, our Chief Executive Officer; Leiv Lea, our Chief Financial Officer; and Mehrdad Mobasher, our Chief Medical Officer. Our executive team will begin with a few prepared remarks, and after that we'll move into a question-and-answer session. I want to remind all of you that management's comments today, along with responses to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today and carry risks and uncertainties that could lead actual results to differ materially from what those statements express or imply, including the risks and uncertainties laid out in Corvus' quarterly report on Form 10-Q, which was filed today and with the SEC, as well as other filings the company makes with the SEC from time to time. The company has no obligation to publicly update or revise any forward-looking statements, except as the law requires. With that said, I'd like to hand the call over to Leiv Lea. Leiv?

Leiv Lea

executive
#2

Thanks, Zack. I'll start by giving a brief look at our financial results for the second quarter of 2020, and after that I'll hand things over to Richard for an update on the business. As of June 30, 2020, Corvus held cash, cash equivalents and marketable securities of $59.3 million, versus $78 million on December 31, 2019. R&D expenses for the second quarter of 2020 came to $7.9 million, versus $10.6 million during the same period in 2019. That $2.7 million decline was driven mainly by a $0.5 million drop in ciforadenant clinical trial expenses, a $1.7 million drop in CPI-006 drug manufacturing costs, a $0.5 million drop in CPI-818 drug manufacturing costs, and a $0.8 million drop in outside service costs; a $1.1 million rise in CPI-006 clinical trial expenses partially offset this. Net loss for the second quarter of 2020 was $10.6 million, versus a net loss of $13.0 million during the same period in 2019. Total stock compensation expense for the second quarter of 2020 was $1.4 million, versus $1.9 million during the same period in 2019. Looking ahead, we anticipate net cash used in operating activities for the second half of 2020 will land between $12 million and $14 million, which is a reduction from the $18.8 million of net cash used in operating activities in the first half of 2020. That reduction stems mainly from careful expense management, together with strong prior enrollment in our clinical studies and the emphasis on patient monitoring and follow-up within those studies. Our current forecast also incorporates the incremental activity tied to our Phase I study of CPI-006 in COVID-19, which costs relatively less than our core oncology programs. I'll now hand the call over to Richard.

Richard Miller

executive
#3

Thanks, Leiv, and hello to everyone this afternoon. We appreciate you being with us for the business update covering our second quarter of 2020. During Q2 we achieved solid progress, moving forward with our pipeline of precisely targeted oncology therapies and striving to launch an encouraging new clinical program involving a novel immunotherapy approach for COVID-19 patients. At this point Corvus has 4 programs active in the clinic, each of them uniquely positioned and anticipated to deliver meaningful updates during the second half of the year. Corvus is in the middle of a thrilling chapter right now, and I'd like to thank every member of our team for the remarkable dedication and hard work that got us here in spite of the obstacles created by COVID-19. All things considered, we count ourselves lucky that the pandemic's effect on the company's momentum has been limited to just a small degree; when it comes to our main oncology programs, what we've focused on throughout Q2 and as we move toward the year's second half has largely been keeping watch over patients and getting later-stage trials ready. Thanks to robust patient accrual in our studies, we were able to administer treatment and gather the necessary information prior to any interruptions tied to COVID; as a result, we remained on schedule with the refreshed ciforadenant findings in renal cell cancer that were shared at ASCO, and those taking part in our trials saw no meaningful disruptions. Also, as we shared not long ago, we filed an IND and launched a clinical study evaluating our CPI-006 B-cell-activating antibody for COVID-19; that trial is progressing as expected. Looking ahead, we'll work hand in hand with our investigators to advance these programs, and we expect additional data updates before the year is out. We're going to keep pushing forward on that, but not at the expense of the wellbeing and safety of the people who work for us, the clinical partners we collaborate with, and the patients those partners care for. On top of that, to keep our studies running, we've stayed in steady contact with the partners who handle our manufacturing, and as things stand, there's no meaningful disruption to our supply of drug. Turning now to a program update, and we'll start with ciforadenant, the small-molecule inhibitor we're developing that goes after the adenosine A2A receptor. At the end of May, during the ASCO20 Virtual Scientific Program, we presented fresh clinical data from the Phase Ib/II trial of ciforadenant in people with advanced refractory renal cell carcinoma, which we refer to as RCC. At ASCO, the findings confirm and build upon the ciforadenant research published in Cancer Discovery back in January 2020. That earlier work highlighted the identification and promise of the Adenosine Gene Signature — a first-of-its-kind biomarker that Corvus discovered to pinpoint individuals who would probably benefit from ciforadenant. In that dataset of 51 patients, a 17% overall response rate per RECIST was observed with ciforadenant among the 30 evaluable patients who were selected using the Adenosine Gene Signature. In addition to the 5 partial responses that made up that 17% rate, tumor shrinkage occurred in 6 more patients but didn't reach the threshold for PR. Among these 30 individuals, the median number of earlier treatments was 3, and 86% had not responded to previous anti-PD-1 therapy. Looking at the other 21 patients who tested negative on the adenosine signature, none of them responded. We've kept working on sharpening how well our biomarker predicts outcomes, and at ASCO we reported an ORR—overall response rate—of 26.7%, this time using the CD68 marker found on myeloid cells. What was shown at ASCO lined up with earlier findings that confirmed ciforadenant's antitumor activity in RCC among patients who had been heavily pretreated, and it keeps bolstering the case for the adenosine signature as a biomarker capable of predicting which patients are most likely to benefit from ciforadenant. We intend to meet with FDA in Q4 of this year to discuss the trial design and our strategy for a randomized pivotal study of ciforadenant in renal cell cancer patients who are in the second line, third line, or beyond, and who have the refined Adenosine Gene Signature biomarker. In addition, we're exploring whether a single-arm trial centered on the adenosine signature would be appropriate, considering how poorly outcomes tend to be for this population when treated with standard options such as I/O agents and TKIs. Keep in mind that this signature identifies a group of patients with especially grim prospects—essentially a novel subset of RCC—and our belief is that those who test biomarker-positive will do well on ciforadenant yet fare poorly with standard therapies, presenting a potential choice in a space where needs remain unmet. Turning to CPI-006, our anti-CD73 antibody that activates B cells, beginning with our oncology program. Altogether, more than 90 patients have been enrolled so far in this trial, which is assessing CPI-006 by itself, paired with ciforadenant, paired with pembrolizumab, and as a triplet alongside ciforadenant and pembrolizumab. Enrollment has closed for the first 3 groups, and we're still enrolling in the triplet combination arm. We expect to stay on schedule and present an update on this work later in the year. Moving beyond oncology. Enrollment is also progressing nicely in our Phase I dose-escalation trial of CPI-006 among COVID-19 patients; we believe CPI-006 could become a novel immunotherapy for treating COVID-19. When it comes to treating COVID-19, no other therapy under investigation that we know of works the way this one does. It activates the adaptive immune system, which increases anti-SARS-CoV-2 antibody levels along with memory B cells. Patients could benefit because their infection might become less severe and last a shorter time, and there's also a chance that longer-lasting protection against getting infected again could be built up. If the treatment proves successful, our expectation is that CPI-006 will turn into a key choice for many different COVID-19 patients, not just the original mild-to-moderate symptom group studied at first; additionally, our clinical trial might provide proof-of-concept for deployment during future outbreaks caused by the present strain, a similar coronavirus strain, or other viruses. This trial got underway in early July, and the plan is to sign up as many as thirty patients who are in the hospital, spread over four groups. Each group receives one dose, either 0.3, 1.0, 3.0, or 5.0 milligrams per kilogram. While the study runs, everyone enrolled will receive the usual COVID-19 treatment. Efficacy is primarily gauged by looking at how serum immunoglobulin, IgM and IgG, and anti-SARS-CoV-2 titers shift from baseline to day 28. On top of that, antibody levels will be followed over a six-month period, which lets us assess what happens with long-term immunity. This study is also examining safety and additional clinical endpoints, including how long it takes for symptoms to resolve, virus clearance as measured by PCR, and the length of time patients stay in the hospital. Right now, five of five participants in the second cohort have completed enrollment—four were already in, and word came through just moments ago that the last one had joined. That brings our total to 10 people taking part. No toxicities have shown up so far, and the preliminary data on anti-SARS-CoV-2 antibodies looks highly promising; we're seeing fairly elevated IgM and IgG titers against both the spike and receptor-binding domain viral proteins. Among the initial 2 patients given CPI-006 at the lowest dose, day 7 IgG titers against spike protein came in above 1 to 25,000 and above 1 to 50,000. A participant in this group finished their day-14 assessment, and the results show antibody titers against the viral spike protein as well as RBD climbing past 100,000 — above 100,000. For such an early stage, those numbers are remarkably elevated. On top of that, notable quantities of IgM antibodies showed up in testing.

Richard Miller

executive
#4

We're going to follow these patients as time goes on, looking at how long immunity lasts and what happens with memory B cells. Given how far we've come and where things stand right now, we think we're still positioned to get the study enrolled quickly and to report 28-day follow-up data on antibody titers for patients at some point in the latter portion of this year, perhaps at SITC in November, where there are now sessions focused on COVID-19. Should the study hit its subjectives, Corvus plans to collaborate with FDA on running a randomized, double-blind, placebo-controlled pivotal trial to back a regulatory submission seeking FDA approval. Our strategy involves assessing CPI-006 in the outpatient as well as the inpatient setting. Treatments in the outpatient setting hold considerable appeal, since this patient group represents a growing share of the COVID-19 pandemic. Finally, regarding CPI-818, our ITK inhibitor, enrollment is now complete in the dose-escalation portion of the Phase I/Ib clinical trial, which enrolled patients across several types of advanced refractory T-cell lymphomas. Among the results was a confirmed and durable complete response in 1 patient with peripheral T-cell lymphoma, who had previously failed chemotherapy as well as high-dose chemotherapy followed by autologous bone marrow transplantation. We've chosen the optimum dose of CPI-818 and are now enrolling patients into the next portion of the study, focusing on those with PTCL, peripheral T-cell lymphoma, and cutaneous T-cell lymphoma; this leaves us well positioned for studies down the road, in lymphoma as well as in autoimmune diseases. We intend to share data on CPI-818 for T-cell lymphomas at the ASH meeting in December. To sum up, we kept up solid momentum across our pipeline, and the second half of the year should bring significant updates for each of our programs. Among the key milestones in the second half are our FDA meeting to talk over a pivotal, biomarker-driven study of ciforadenant in RCC, which might start early next year; fresh data on CPI-006 and CPI-818 at upcoming oncology meetings; and ongoing enrollment plus data readouts from our Phase I study of 006 for COVID-19. We're eager to bring you an update on how things are going later this year. At this point I'll hand the call to the operator for Q&A. Operator?

Mara Goldstein

analyst
#5

Can you hear me?

Richard Miller

executive
#6

Hello?

Mara Goldstein

analyst
#7

Am I coming through? Richard, hello there — is my voice reaching you?

Richard Miller

executive
#8

Mara, that's right, I'm picking you up fine.

Mara Goldstein

analyst
#9

Sure. Could you walk us through a bit more about the patients in the PR and 818 study — and what that study might look like in CTCL? Would it match up with the PTCL group you described?

Richard Miller

executive
#10

You want some color on the peripheral T-cell lymphoma patient? She was a fairly typical case — diffuse lymphadenopathy that hadn't responded to CHOP chemo, which is a standard treatment for PTCL. After that, she received high-dose chemo plus a bone marrow transplant. She relapsed not long after. When she entered our study, her disease was progressing. She took 818 as part of the trial — one tablet, two times daily — and stayed on it for multiple months. Gradually, her lymphadenopathy completely resolved, as shown on CT and PET imaging and verified by later scans — a CR according to RECIST or whatever lymphoma criteria you prefer. As for what comes next, we plan to bring in additional PTCL and CTCL patients so we can build up the numbers in those two subgroups. Those represent two of the most frequent T-cell lymphoma subtypes. They behave quite differently. PTCL tends to be faster-growing and more aggressive. CTCL is more of a chronic condition. We'd like to gather more information on both. In CTCL, we have observed responses that don't quite hit — during our dose escalation — the bar for RECIST yet, nor Cheson or Lugano criteria, though they come very near. We're still tracking those patients, and we intend to dig deeper into those efficacy signals among patients enrolled later. And — what else were you asking?

Mara Goldstein

analyst
#11

I believe that covered it; however, may I follow up regarding the RCC study and the Adenosine Gene Signature — what would the range, I guess, of potential results look like, in terms of how the adenosine signature would be applied following your conversation with the FDA? So when we consider — does it apply to everyone, and you'd simply have separate stratification groups built on it? Or would — is your aim to be able to enroll patients according to adenosine signature?

Richard Miller

executive
#12

That question will be handled by Dr. Mobasher, who has put substantial effort into this area. Mehrdad?

Mehrdad Mobasher

executive
#13

Absolutely. Right, so what we're leaning toward right now is that the Phase III trial will take patients of any type, yet we'll capture adenosine signature status when they enter the study, and stratification will happen according to that signature. That said, statistical power for the trial will rest on the adenosine signature-positive group, while the negative group will still provide utility. From that, we'll gain substantial insight into the negative population, and it will also aid us in deepening our grasp of both the signature and the biomarkers.

Tony Butler

analyst
#14

Richard, I've got 3 questions, honestly. Suppose you ran a study right now using an A2A receptor antagonist in something other than RCC — would adenosine signature still serve as your biomarker? Or does that marker really belong more to an RCC study involving an A2A receptor antagonist? That's my first one. Question two concerns 006. Since 3 cohorts have finished dosing and are under monitoring, could you share your thinking about what might show up later this year when some data gets presented? Would it come from all 4 cohorts — and would we be able to tell 1 of the 4 cohorts apart, or perhaps 2, from the remaining 1 or 2? That's the second one. My third question: when it comes to funding 006 for COVID, is there some mechanism where DARPA could assist with part of that funding? Or would you shoulder it entirely on your own?

Richard Miller

executive
#15

Okay. Well, this tests my memory, Tony, so I'll do my best with all 3. First question: yes. Second question: combo. Third question: yes. No, seriously — regarding your first one, the answer is that we would indeed employ the adenosine signature in other tumors. That signature shows up in plenty of other tumors, though the degree varies. We would certainly investigate it in other solid tumors. Whether I'd limit enrollment based on it yet, I'm not sure, since our knowledge of how predictive the adenosine signature is in other tumors remains insufficient — but it's definitely worth examining. So essentially, any patient — I'd say a note of caution here — anyone employing an agent that blocks adenosine mediators for any purpose would be smart to examine the adenosine signature, CD73 included. So yes, we'd use it; however, its function in other tumors isn't as well characterized as what we have for renal cell cancer. With renal cell cancers, obviously — no statistics needed here — you get roughly 20% good responses against 0. Now, on your second question about 006, we've examined monotherapy, we've examined combo with ciforadenant, we've examined combo with pembro, and we've examined triplet. Combinations appear better, and the triplet looks quite interesting. But that's really all I can say at this point. There's another piece to this, which is interesting too. Keep in mind we've now examined all sorts of cancers. And the — none of these individual arms has the power to demonstrate that one beats another. There simply aren't enough patients, and there are multiple different cancer histologies. Yet one thing in the cancer narrative I expect will prove quite fascinating is how antibodies get induced against particular tumors, plus what part those induced antibodies could play in how a tumor responds; then the third item raised concerned COVID-19 and looking into government funding requests. That's something we're examining. We have and continue to have certain submissions ready. Still, right now, additional data is what we require. This whole space is brand new. More clinical data and more safety data — that's what we intend to obtain. What we're seeing from antibody data in vivo is pretty compelling. Alongside that, truly remarkable things are occurring in vitro; put differently, B cells and antibody responses can be modulated even in vitro. My hope is that we'll deliver a really strong presentation pulling all of it together at the SITC meeting this November. Still, the biology involved here is genuinely compelling. Keep in mind that my group at Corvus possesses some familiarity with these cells, since we've worked on a few drugs you might recognize: Rituxan, ibrutinib, and at present 006.

Tony Butler

analyst
#16

Richard, one more thing, please. I value the way you laid that out. That said, let's return to the 006 combos being studied in oncology. My motivation for raising it is that situations can arise — take PD-1, for instance — when you're treating refractory patients, as is the case here, and in quite a few of those cohorts PD-1 plainly isn't going to be effective. So a sizable set of patients could be refractory to PD-1, and even so, results might turn out superior in a single combination, or in the triplet, compared with what the other combination delivers. Honestly, that is the point I'm attempting to push toward with this question, if you follow me.

Richard Miller

executive
#17

Right. Well, I understand the nature of your inquiry. Is it possible to take a tumor that's refractory to PD-1, colon cancer perhaps, and all at once render it responsive? Honestly, whether we'll ever possess that sort of data, I can't say, yet I see the direction you're headed; so...

Tony Butler

analyst
#18

Perhaps in non-small cell lung cancer.

Richard Miller

executive
#19

Alternatively, you might use a tumor that responds to PD-1 but has stopped doing so, or a similar scenario, and bring back that response. That appears to be what happens with renal cell. What you can infer about renal is that when a PD-1 treatment fails — and we observe both categories of patients; we observe those who are genuinely refractory to PD-1. In other words, the disease progresses straight through a PD-1. Then we administer a combination to them, and they have a response. We also observe individuals who initially respond to a PD-1, later fail, and then you manage to recapture that response afterward once you combine them. So, as you are aware, those may involve quite distinct mechanisms.

Arthur He

analyst
#20

Can you guys hear me?

Richard Miller

executive
#21

Yes.

Arthur He

analyst
#22

I have two things. First, about the design of the pivotal RCC trial, I just want to get clarity: will you be employing the initial adenosine signature that you put forward as a biomarker, or will you also be employing CD68 plus as a biomarker? Could you clarify that for me? And the second thing concerns — the second thing concerns CPI-006 in the COVID study. I'm just wondering, have you assessed the neutralizing antibody titer?

Richard Miller

executive
#23

Yes. Okay. Let me address those questions. The first one about the signature. We are doing a great deal of work on the signature, and it will be some combination of what you've brought up; put differently, all of those can be incorporated into the same sort of gene signature; so we've kept refining that somewhat, and we're still examining it. But essentially, it centers on these genes that get expressed in myeloid cells, among them those CD68 cells; now the second question about neutralizing antibodies, yes, these patients are producing neutralizing antibodies. I noted on my call — on the call we just held that this day 14 patient had an anti-RBD of more than 100,000. If you have a titer of more than 100,000 against the receptor-binding domain, I promise you there will be very high neutralization. There's — every study is demonstrating a very tight correlation between anti-RBD and neutralization. I mean in the end, people won't perform neutralization because it's a far harder assay, and the RBD is far easier. But the correlation is very strong; but if you get titers of 100,000 to RBD, that is definitely going to neutralize.

Richard Miller

executive
#24

Alright, I appreciate all of you joining this conference call. Naturally, as the year moves along, we're eager to share additional updates regarding each of the programs. Many thanks.

Operator

operator
#25

That brings us to the end of today's conference call. You can now hang up. Thanks for joining us, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.